Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

Inclusion Criteria: * Participation in the preceding A0081066 double-blind trial met the entry criteria for that trial and completed A0081066 study through visit 7 Exclusion Criteria: * Experienced serious adverse event during the A0081066 trial that was considered related or possibly related to study medication by the investigator or sponsor * non-compliant during A0081066 trial * clinically significant or unstable medical condition both HIV-related and non-HIV related including but not limited to, cardiac, pulmonary or hepatorenal disease that, in the opinion of the investigator, would compromise participation in the study